GenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ® Named Early Access Program (AAC) in France
Design for dose-ranging study submitted, with clinical trial application targeted for Q3 2025
Opening of AAC targeted for Q4 2025 at the latest
Multiple near-term value catalysts expected over next 12 months
PARIS, June 12, 2025--(BUSINESS WIRE)--Regulatory News:
GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that it has reached agreement with the French medicines safety agency ANSM to consider expeditiously opening the French named early access program (AAC) for LUMEVOQ® upon approval of a dose-ranging clinical study.
Clear Path Forward for LUMEVOQ® AAC Program in France
Following extensive discussions, GenSight reached alignment with ANSM on a plan to open the LUMEVOQ® AAC program. The agency has agreed that the authorization of a focused dose-ranging study could enable the opening of the early access program. The Company has submitted a preliminary design of the study to the agency and aims to finalize the protocol of a dose-ranging study in Q3 2025.
In parallel, the Company will work with the agency to find a solution for patients who may not be included in the study but who may benefit from the AAC program. The AAC program is targeted to open in Q4 2025 at the latest.
"In the interest of clearing the way for patients to be treated with LUMEVOQ, we are pleased to have achieved this important agreement with ANSM on a clear path forward for opening patient access to LUMEVOQ in France" said Laurence Rodriguez, Chief Executive Officer of GenSight Biologics. "We are thankful for the ANSM's ongoing engagement and openness to discussion, as we work towards the shared goal of providing access to LHON patients who urgently need a safe and effective treatment."
Financing Strategy to Support Regulatory Milestones
GenSight is implementing a financing strategy to bridge operations through the opening of the AAC program and prepare for the new global Phase III clinical trial. The Company is actively pursuing various funding initiatives to support these critical regulatory milestones.
"We are working on our financing strategy to manage the bridge between now and the opening of the AAC program and the initiation of the Phase III study," commented Jan Eryk Umiastowski, CFO of GenSight Biologics. "Our focus remains on securing the resources needed to execute our regulatory strategy while exploring additional funding opportunities. "
Advancing Core Marketing Authorization Strategy
In parallel with the French AAC program developments, GenSight will continue to advance its global marketing authorization strategy:
Preparation for regulatory consultations in the US and EU
Planning for the global Phase III trial scheduled to begin in 2026, designed to meet FDA and EMA requirements
Completing the transition to a new manufacturing partner to secure reliable clinical and commercial supply
Advancing preparations for MHRA submission in the United Kingdom
During this period, the Company will actively pursue additional non-dilutive funding opportunities, including licensing arrangements outside North America and Europe and potential M&A activities.
Multiple Value Catalysts
GenSight anticipates a number of significant value-creating events in 2025-2026:
Q3 2025: Clinical trial application for focused dose-ranging study
Q4 2025: Completion of manufacturing tech transfer
Q4 2025: Opening of the AAC program
Q2 2026: Completion of Phase III trial preparations
Early H2 2026: Initiation of global Phase III clinical trial
Early H2 2026: pre-submission meeting with MHRA
Financial Position
The Company received €0.7 million of its Research Tax Credit (CIR) end of May, with the remaining €0.4 million to be paid in July 2025. Based on current operations and projections, GenSight's cash will support operations until mid-July 2025.
The Company acknowledges that current funds are insufficient to cover operational requirements for the next 12 months. The planned financing initiatives are designed to extend the cash runway and enable the initiation of the Phase III clinical trial and UK MHRA marketing application for LUMEVOQ®.
As of June 12, 2025, the number of outstanding GenSight Biologics shares was 131,466,495 ordinary shares.
Risk factors
Detailed information regarding the Company, including its business, financial information, results, perspectives and related risk factors are contained (i) in the Company's 2024 Universal Registration Document filed with the AMF on April 8, 2025 under number D.25-0234. This document, as well as other regulated information and all of the Company's press releases, can be accessed on the Company's website (www.gensight-biologics.com) and/or AMF (www.amf-france.org). The reader's attention is drawn to the risk factors related to the Company and its activities presented in chapter 3 of its 2024 URD in particular the liquidity risk presented in the chapter 3.1.1.
About GenSight Biologics
GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, GS010 (lenadogene nolparvovec) is in Phase III in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding product development prospects and financial projections. These statements do not constitute guarantees of future performance and involve risks and uncertainties. While the Company is actively pursuing financing solutions, regulatory requirements necessitate disclosure that material uncertainty exists regarding the Company's ability to continue as a going concern if sufficient funding cannot be secured. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in GenSight Biologics' regulatory filings with the French Autorité des Marchés Financiers. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, GenSight Biologics undertakes no obligation to update or revise the information contained in this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250612867666/en/
Contacts
GenSight Biologics Chief Financial Officer Jan Eryk Umiastowski jeumiastowski@gensight-biologics.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
a few seconds ago
- Fast Company
Spirit's survival hinges on finding more cash
NEWS Without a cash boost, the budget airline's comeback could stall out. [Photos: David Sypher /Unsplash, Yeti Studio/Adobe Stock] BY Spirit Airlines can't seem to reach its cruising altitude. The budget airline issued a warning late Monday that if it doesn't find an infusion of cash, its business is poised to fail. Spirit expressed the dire state of its financials in its quarterly earnings report, filed late Monday. The report comes less than six months after the beleaguered airline emerged from bankruptcy with a plan to right its business and pursue profitability. 'Management has concluded there is substantial doubt as to the Company's ability to continue as a going concern within 12 months from the date these financial statements are issued,' the company wrote in the filing, citing a scenario in which the company fails to hold the liquid assets needed to meet its debt obligations and keep its credit card processor. To steer itself out of the crisis, Spirit is pursuing 'liquidity enhancing measures' that could include selling some of its aircraft or real estate and offloading some of its extra airport gate capacity. 'While it is the Company's goal to execute on these initiatives, there can be no assurance that such initiatives will be successful,' the company wrote. Spirit cut 200 jobs back in January as part of its plan to slash $80 million in costs. Last year, the company sold 23 Airbus planes – more than 10% of its fleet – to drum up emergency cash. 'As you all know, we're facing significant challenges with our business, which is why we've been focused on taking actions to optimize our organization and create more efficiencies,' Spirit CEO Ted Christie told staff in an internal memo early this year. 'The bottom line is, we need to run a smaller airline and get back on better financial footing.' Recent problems, Frontier bailout Spirit filed for Chapter 11 bankruptcy late last year in light of mounting losses, a pile of debt and failed merger negotiations. The airline continued to operate during that time frame, which coincided with the busy holiday travel season. 'The most important thing to know is that you can continue to book and fly now and in the future,' the company wrote in an open letter to customers at the time. Spirit was in talks with JetBlue to combine the two airlines back in 2023, but the ill-fated merger faced stiff opposition. The Justice Department sued to block the $3.8 billion deal over antitrust concerns and ultimately a federal judge sided with the government, sounding the merger's death knell. Earlier this year, Spirit rejected a different merger offer from fellow budget carrier Frontier. Frontier revised the offer, but Spirit declined to move forward with the deal, which would have been worth around $2.16 billion. At the time, the company insisted that going it alone and pursuing its post-bankruptcy restructuring plan would benefit shareholders more than doubling up with another airline. The airline industry is in a strange transitional phase in 2025. Normal U.S. carriers are looking to rebrand themselves as 'lifestyle' airlines while credit card companies double down on luxe travel perks designed to make air travel more bearable. The industry's already wafer-thin margins are threatened by Trump's endless parade of tariffs and the economic chaos they sow. Meanwhile, a spate of U.S. aviation disasters has led to tanking trust in air travel and calls for a national overhaul of the air traffic control system that undergirds the whole industry. How – and if – budget airlines fit into the future of travel is an open question, but it's one Spirit needs to answer if it plans to survive. Unfortunately for the troubled airline, time is running out. The early-rate deadline for Fast Company's Most Innovative Companies Awards is Friday, September 5, at 11:59 p.m. PT. Apply today. ABOUT THE AUTHOR Taylor Hatmaker is a writer and photographer based on the West Coast. She was previously a Senior Editor at TechCrunch, where she specialized in social media, gaming and online culture. More
Business Wire
a few seconds ago
- Business Wire
Spectrum Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights
LOS ANGELES--(BUSINESS WIRE)-- The DJS Law Group reminds investors of a class action lawsuit against Spectrum Pharmaceuticals, Inc. ('Spectrum' or 'the Company') (NASDAQ: SPPI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of SPPI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: DEADLINE: September 24, 2025 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Spectrum's Pinnacle Study of poziotinib for the treatment of lung cancer was less positive than it portrayed to investors. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. If you are a shareholder who suffered a loss, contact us to participate. NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of SPPI during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. There is no cost or obligation to you to participate in this case. WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results. Join the case to recover your losses. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
an hour ago
Driver faces up to $110,000 in fines for speeding
GENEVA -- The driver was clocked going 27 kilometers per hour (17 mph) over the speed limit on a street in the Swiss city of Lausanne, and now he's facing up to 90,000 Swiss francs (over $110,000) in fines as a result. But he can afford it. Why the eye-popping penalty? Because the speedster, a repeat offender, is one of Switzerland's wealthiest people, and the Vaud canton, or region, serves up fines based on factors like income, fortune or general family financial situation. The Swiss are not alone. Germany, France, Austria and the Nordic countries all issue punishments based on a person's wealth. The recent fine isn't even a record in Switzerland. In 2010, a millionaire Ferrari driver got a ticket equal to about $290,000 for speeding in the eastern canton of St. Gallen. Back then, the Swiss safety group Road Cross said rich drivers had been lightly punished until voters approved penal law overhaul three years earlier that let judges hand down fines based on personal income and wealth for misdemeanors like speeding and drunk driving. Under today's rules, an indigent person might spend a night in jail instead of a fine, while the wealthiest in the rich Alpine country could be on the hook for tens of thousands. A court in the Swiss canton of Vaud recently ruled that the tycoon must pay 10,000 Swiss francs ($12,300) up front and could be forced to pay the rest — 80,000 more — if he's caught for a similar roadway infraction over the next three years. Switzerland's '24 Heures' newspaper first reported the case and said the man, who was not identified, was a French citizen listed by Swiss economic weekly Bilan among the 300 richest people in Switzerland — with a fortune in the hundreds of millions of dollars. The daily reported that an automated police radar photographed the offender driving at 77 kilometers per hour (48 mph) in a 50 kph (31 mph) zone on a Lausanne street. A quick-calculating prosecutor tallied the maximum fine the driver faced under the law, the report said. Vincent Derouand, a spokesperson for the Vaud public prosecutors office, said the defendant didn't contest the decision, which was handed down in June for the infraction nearly a year ago — in August 2024. The Vaud criminal code sets a maximum financial penalty based on the "personal and economic situation of the offender at the time of the ruling' — notably taking into account issues like income, fortune, lifestyle and family financial needs. The newspaper reported that he had already been caught for a similar speeding infraction eight years ago, and also paid 10,000 Swiss francs in penalty and faced another 60,000 if another infraction had taken place within the following two years. In Switzerland, penalties for speeding can even catch up with the cops: One officer was fined for racing at nearly twice the speed limit through Geneva streets back in 2016 while chasing thieves who had blown up a bank teller machine.
